Holly J Meany

Summary

Affiliation: Children's National Medical Center
Country: USA

Publications

  1. pmc Pediatric phase I trial design using maximum target inhibition as the primary endpoint
    Holly Meany
    Department of Hematology Oncology, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    J Natl Cancer Inst 102:909-12. 2010
  2. doi request reprint 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)
    Holly Meany
    Department of Hematology Oncology, Children s National Medical Center, Washington, DC, USA
    Pediatr Blood Cancer 60:59-64. 2013
  3. ncbi request reprint Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma
    Holly J Meany
    Department of Pediatric Hematology Oncology, Children s National Medical Center, Washington, District of Columbia 20010, USA
    Pediatr Blood Cancer 48:399-402. 2007
  4. ncbi request reprint The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
    Holly J Meany
    Children s National Medical Center, Washington, DC, USA
    Cancer Chemother Pharmacol 62:387-92. 2008
  5. pmc Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor
    Holly J Meany
    Department of Pediatric Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
    J Immunother 31:679-83. 2008
  6. doi request reprint Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
    Holly J Meany
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg 10 CRC Rm 1 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:137-42. 2009
  7. pmc Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro
    Holly J Meany
    Department of Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
    Pediatr Blood Cancer 54:47-54. 2010

Detail Information

Publications7

  1. pmc Pediatric phase I trial design using maximum target inhibition as the primary endpoint
    Holly Meany
    Department of Hematology Oncology, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    J Natl Cancer Inst 102:909-12. 2010
    ..This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents...
  2. doi request reprint 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)
    Holly Meany
    Department of Hematology Oncology, Children s National Medical Center, Washington, DC, USA
    Pediatr Blood Cancer 60:59-64. 2013
    ..Magnetic resonance imaging (MRI) with volumetric analysis and 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) were utilized to monitor symptomatic nodular lesions...
  3. ncbi request reprint Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma
    Holly J Meany
    Department of Pediatric Hematology Oncology, Children s National Medical Center, Washington, District of Columbia 20010, USA
    Pediatr Blood Cancer 48:399-402. 2007
    ..Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients...
  4. ncbi request reprint The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
    Holly J Meany
    Children s National Medical Center, Washington, DC, USA
    Cancer Chemother Pharmacol 62:387-92. 2008
    ..We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics of erlotinib and its active metabolite OSI-420 after an intravenous (IV) dose in a non-human primate model...
  5. pmc Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor
    Holly J Meany
    Department of Pediatric Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
    J Immunother 31:679-83. 2008
    ..The combination was well tolerated. Although grade 3/4 adverse events were reported, dose adjustments were not required. Toxicities resolved without significant interventions...
  6. doi request reprint Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
    Holly J Meany
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg 10 CRC Rm 1 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:137-42. 2009
    ..Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide...
  7. pmc Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro
    Holly J Meany
    Department of Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
    Pediatr Blood Cancer 54:47-54. 2010
    ....